← back to search

Daniel P. Hart

Amsterdam UMC Location Vrije Universiteit Amsterdam · NL
Area of research
Hematology · Genetics
Research interest
Research interests include Hemophilia Treatment and Research, Platelet Disorders and Treatments, Blood Coagulation and Thrombosis Mechanisms, and Coagulation, Bradykinin, Polyphosphates, and Angioedema.
h-index
36
citations
6,518
works
101
NIH funding
primary concept
Haemophilia
email

Recent publications

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
New England Journal of Medicine 2023cited by 336position: middledoi
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
2023cited by 19position: contributordoi
Considerations for shared decision management in previously untreated patients with hemophilia A or B.
2023cited by 12position: contributordoi
International consensus recommendations on the management of people with haemophilia B
Therapeutic Advances in Hematology 2022cited by 40position: firstdoi
International consensus recommendations on the management of people with haemophilia B.
2022cited by 30position: contributordoi
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC.
2022cited by 17position: contributordoi
Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC.
2021cited by 41position: contributordoi
Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study
Orphanet Journal of Rare Diseases 2021cited by 26position: firstdoi
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update.
2021cited by 22position: contributordoi
Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
2021cited by 5position: contributordoi
The factor VIII treatment history of non-severe hemophilia A-Response from original authors Abdi et al.
2021cited by 1position: contributordoi
Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach" - Will we ever be able to avoid inhibitor formation in hemophilia A?
2021cited by 0position: contributordoi
Re-personalization and stratification of hemophilia care in an evolving treatment landscape.
2019cited by 4position: contributordoi
Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data
Scientific Reports 2018cited by 90position: middledoi
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
Research and Practice in Thrombosis and Haemostasis 2018cited by 58position: middledoi
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders
Blood 2016cited by 184position: middledoi
Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia
Blood 2016cited by 52position: middledoi
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
Blood 2013cited by 215position: middledoi
The incidence and magnitude of fibrinolytic activation in trauma patients
Journal of Thrombosis and Haemostasis 2012cited by 480position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mike Makris · University of Vermont3 papers (2021–2022) · 3 papers (2021–2022)Víctor Jiménez‐Yuste · Hospital Universitario La Paz3 papers (2021–2022)Flora Peyvandi · Goethe University Frankfurt2 papers (2021–2022)Robert F. Sidonio · Emory University2 papers (2021–2022)Andreas Tiede · European Hematology Association2 papers (2022–2022)Wolfgang Miesbach · Goethe University Frankfurt2 papers (2021–2022) · 2 papers (2021–2022)Pratima Chowdary · Springer Nature2 papers (2021–2022) · 2 papers (2021–2022)Robert Klamroth · University of Bonn2 papers (2021–2022)Sean Platton · Queen Mary University of London2 papers (2012–2022) · 1 papers (2021–2021)Claire Lentaigne · Imperial College Healthcare NHS Trust1 papers (2016–2016)David Lillicrap · Medical College of Wisconsin1 papers (2018–2018)Sarah K. Westbury · Hospital for Sick Children1 papers (2016–2016) · 1 papers (2021–2021)Sofia Papadia · University of Edinburgh1 papers (2016–2016)Kathelijne Peerlinck · KU Leuven1 papers (2016–2016)Jonathan Stephens · NHS Blood and Transplant1 papers (2016–2016)